The reduced arterial oxygen tension at high altitude impairs the ability to work. Acetazolamide improves arterial oxygen saturation (SaO 2 ) by increasing ventilation but is associated with an increased work and cost of breathing. Depending on the settings, sildenaWl can also increases SaO 2 possibly through a reduction in pulmonary hypertension and interstitial edema, which could improve ventilation-perfusion matching. The objective of this study is to determine the eVects of acetazolamide and sildenaWl on ventilatory control and breathing eYciency (V E /VCO 2 ) during submaximal steady-state hypoxic exercise in healthy individuals. Following 18 h of hypoxic exposure in an altitude tent at an oxygen concentration of 12.5% (simulated altitude of 4,300 m), 15 participants performed 10 min of hypoxic exercise on a stationary bicycle at 40% of their sea level peak oxygen uptake (VO 2 ) while randomly receiving sildenaWl 40 mg (SIL), acetazolamide 125 mg (ACZ) or a placebo (PLA). There was no diVerence in VO 2 during exercise between conditions while SaO 2 was greater with acetazolamide compared to both placebo and sildenaWl. Acetazolamide increased ventilation (PLA 49.0 § 3.2, SIL 47.7 § 3.1, ACZ 52.1 § 3.0 l/min) and reduced end-tidal CO 2 (P ET CO 2 ) (PLA 32.1 § 0.8, SIL 32.8 § 0.9, ACZ 29.2 § 0.7 mmHg) compared to placebo and sildenaWl. Breathing was less eYcient with acetazolamide (increased V E /VCO 2 ) in comparison to placebo and sildenaWl (PLA 41.5 § 1.0, SIL 40.4 § 1.3, ACZ 45.4 § 1.0) while sildenaWl did not change V E /VCO 2 during hypoxic exercise. In conclusion, acetazolamide increased ventilation and reduced breathing eYciency while sildenaWl did not aVect breathing eYciency despite a trend toward a blunted ventilatory response, possibly due to a reduction in pulmonary hypertension and/or ventilatory drive, during submaximal hypoxic exercise in healthy individuals.
Introduction
The decreased partial pressure of oxygen at altitude results in reduced alveolar (PAO 2 ) and arterial (PaO 2 ) partial pressures of oxygen (Greene 1934) . Hypoxemia stimulates the peripheral chemoreceptors which lead to an increase in ventilation in an attempt to maintain homeostasis (Rahn and Otis 1948) . The maintenance of PaO 2 at altitude is further complicated by increased oxygen diVusion limitations and/or ventilation-perfusion mismatching, possibly due to heterogeneous hypoxia-induced pulmonary vasoconstriction and/or transient changes in lung Xuid balance (Capen and Wagner 1982; Ghofrani et al. 2004) . Oxygen diVusion limitation and ventilation-perfusion mismatching may be particularly prominent during exercise (Fulco et al. 1998; Kjaergaard et al. 2007 ). Moreover, the hyperventilation required to increase alveolar and arterial oxygen levels during exercise may come at an increased cost as the work of breathing is 40-60% greater at altitude than at sea level for any given exercise intensity (Dempsey et al. 1977 ; Thoden et al. 1969) .
Acetazolamide is commonly prescribed to improve arterial oxygenation and prevent acute mountain sickness in mountain climbers (Hackett and Roach 2001) . Acetazolamide is a carbonic anhydrase inhibitor that decreases the renal absorption of bicarbonate and induces a metabolic acidosis which triggers an increase in ventilation and results in a lessening of hypoxemia (Faoro et al. 2007a; Swenson 1998 ). However, acetazolamide has been reported to reduce breathing eYciency during hypoxic exercise (Garske et al. 2003; Schoene et al. 1983 ), resulting in a reduced aerobic capacity and an increased perception of leg fatigue (Garske et al. 2003) . Indeed, an excessive ventilatory responsiveness to hypoxic exercise due to acetazolamide would further increase the work of breathing and could result in a competition between respiratory and locomotor muscles at a time when oxygen delivery is already challenged (Smith et al. 2001) . Although acetazolamide is commonly prescribed in mountain climbers, other drugs have been shown to improve arterial oxygenation at altitude.
It has been previously suggested that sildenaWl decreases pulmonary hypertension and possibly mild interstitial edema at altitude, which could improve ventilation-perfusion matching and increase PaO 2 (Hsu et al. 2006) . SildenaWl is a phosphodiesterase-5 inhibitor that causes pulmonary vasodilation by reducing smooth muscle tone through an increase in cyclic GMP and local availability of nitric oxide resulting in a reduction in pulmonary artery pressure (Ghofrani et al. 2004; Sebkhi et al. 2003; Zhao et al. 2001) . SildenaWl has been shown to attenuate the decline of arterial oxygen saturation during normobaric hypoxic exercise (Faoro et al. 2007b; Ghofrani et al. 2004; Hsu et al. 2006; Kolluru et al. 2008; Ricart et al. 2005; Zhao et al. 2001) . Pulmonary hypertension and mild congestion induced by hypoxia may also stimulate ventilation through receptors such as pulmonary unmyelinated C-Wber receptors (Roberts et al. 1986 ). Thus, during exercise at altitude, sildenaWl may not only improve breathing eYciency through altered ventilation-perfusion matching in the lung, but may also decrease ventilatory drive by reducing pulmonary hypertension and congestion. No previous studies directly compared the eVects of sildenaWl and acetazolamide on breathing eYciency during hypoxic exercise. Therefore, the purpose of this study was to examine the eVects of sildenaWl and acetazolamide on breathing eYciency, as measured by minute ventilation/carbon dioxide output (V E /VCO 2 ) (Kleber et al. 2000) , and indices of ventilatory control during submaximal hypoxic exercise in healthy individuals.
Methods
Fifteen healthy individuals (seven men and eight women) participated in the study. Participants were excluded from the study if they had diabetes, coronary artery disease, known lung disease or renal insuYciency, hypertension (arterial blood pressure >140/90 mmHg), severe headaches once a week or more, history of migraine headaches in the last 6 months or were taking alpha blockers or nitrates. Participants also underwent a cardiovascular and lung examination performed by a cardiologist. All participants gave written informed consent after being provided a description of study requirements. This study was conducted in accordance with the Declaration of Helsinki and approved by the Mayo Clinic Institutional Review Board. All procedures followed institutional and Health Insurance Portability and Accountability Act (HIPAA) guidelines.
Study protocol
Participants performed an incremental exercise test to exhaustion on a cycle ergometer to determine peak oxygen uptake (VO 2 peak) while breathing normal air at sea level. Initial workload was set at 30 W and workload was increased by 30 W for women and 40 W for men with each 2-min stages. Breath by breath data was collected and analyzed every 5 s using a Medical Graphics metabolic system (St Paul, MN). In an attempt to challenge lung Xuid balance, participants were subsequently exposed to 18 h of hypoxia in an altitude tent, which included an overnight stay, on three diVerent sessions separated by at least 24 h. Each hypoxic exposure ended with participants performing 10 min of hypoxic exercise at 40% of normoxic peak VO 2 , a work rate simulating the level of exercise common in a mountain environment. For each visit, participants were pretreated with either 40 mg of sildenaWl (PWzer, New York, NY), 125 mg of acetazolamide (PWzer, New York, NY) or placebo. Study medications were administered in a double-blind fashion at 0600, 1200 and 2200 hours on the study day and at 0600 hours the following morning (Fig. 1) . The sildenaWl dose was selected based on prior reports indicating good tolerability and signiWcant hemodynamic eVect at altitude (Ghofrani et al. 2004; Ricart et al. 2005) while the chosen acetazolamide dose is known to prevent periodic breathing and acute mountain sickness (Hackett et al. 1987) . The dosing intervals assured that an adequate excretion of bicarbonate was achieved prior to and during hypoxic exposure, and that an adequate amount of sildenaWl was present throughout the study.
Participants arrived at the laboratory at 1200 hours and were provided with a standardized meal and had free access to non-caVeinated beverages. At 1400 hours, participants entered a low-oxygen tent (Colorado Altitude Training, Boulder, CO) with an oxygen concentration of 12.5% (simulated altitude of 4,300 m). Participants were given another standardized meal at 1700 hours. Participants were instructed to sleep between 2100 and 0600 hours. At 0800 hours, following 18 h of hypoxic exposure, participants performed 10 min of hypoxic exercise at 40% of peak VO 2 .
Measurements during steady-state submaximal hypoxic exercise Measurements of VO 2 , CO 2 output (VCO 2 ), minute ventilation (V E ), tidal volume (V T ), end-tidal partial pressure of carbon dioxide (P ET CO 2 ), inhalation time (T i ), exhalation time (T e ) and respiration rate (RR) were made using a breath-bybreath analysis system (Medical Graphics St Paul, MN). Breathing eYciency was calculated as V E /VCO 2 (Sun et al. 2002 ) and V T /T i (Milic-Emili and Grunstein 1976) and P ET CO 2 were used as indices of ventilatory drive. Respiratory exchange ratio (RER) was calculated as VCO 2 /VO 2 .
Arterial oxygen saturation (SaO 2 ) and heart rate were continuously monitored with a Wnger pulse oximeter (Nellcor N-595, Pleasanton, California). Systolic and diastolic blood pressures were measured manually by sphygmomanometry and auscultation every 2 min and values were used to calculate mean arterial pressure by the formula [(2 £ diastolic blood pressure) + systolic blood pressure]/3. Hypoxic ventilatory responsiveness (HVR) was calculated as (hypoxic V E ¡ room air V E /hypoxic SaO 2 ¡ room air SaO 2 ). Right ventricular systolic pressure was obtained by measuring the peak velocity of tricuspid regurgitation in the apical four-chamber view and approximated using the Bernoulli equation (Yock and Popp 1984) . Right ventricular systolic pressure was estimated by Doppler echocardiography before exercise, immediately upon exercise completion and 10 minutes into recovery. Subjects completed the Lake Louise questionnaire for symptoms of high altitude sickness with questions ranging from gastrointestinal discomfort to evidence of systemic edema (Lake Louise consensus 1992). Lake Louise score was determined at 1400, 2000 and 0600 hours and the average value was calculated. Participants were also asked to rank their level of dyspnea, chest pain, headache and nausea. Exercise data are presented as an average of the last 7 min of steady-state hypoxic exercise.
Statistical analysis
A one-way analysis of variance was used to determine the eVect of condition (acetazolamide, sildenaWl and placebo). Where interaction eVects were signiWcant, post hoc analyses were performed with Student's paired t test. Pearson's correlation coeYcient was used for the analysis of associations between variables. Results are expressed as mean § SEM. P values <0.05 were considered signiWcant.
Results

Ventilatory responses to hypoxic submaximal exercise
Participants were aged 34.8 § 2.4 years, measured 173.6 § 2.7 cm, weighed 73.8 § 3.7 kg and had a peak VO 2 of 39.3 § 2.6 ml/kg/min. There was no diVerence between Lake Louise scores between acetazolamide, sildenaWl and placebo during hypoxic exposure. A minority of participants experienced mild dyspnea, chest pain, headaches and nausea and there was no diVerence between conditions. Acetazolamide increased V E compared to placebo through an increase in V T and a reduction in RR (Table 1 ). The increase in V E resulted in a reduction in P ET CO 2 and since VCO 2 did not change, V E /VCO 2 increased (Table 1; Fig. 2) . VO 2 and T e did not change with acetazolamide compared to placebo (Table 1) . Acetazolamide increased T i and V T /T i in comparison to placebo. RER was reduced with acetazolamide compared to placebo (Table 1) .
There was a trend toward reduced V E with sildenaWl compared to placebo (P = 0.12) through a nearly signiWcant reduction in RR (P = 0.052) and an increase in V T (Table 1 ; Fig. 2 ). SildenaWl increased both T i and T e while V E /VCO 2 , P ET CO 2 , VO 2 and VCO 2 did not change with sildenaWl compared to placebo (Table 1; Fig. 2 ). The changes in V T and T i induced by sildenaWl resulted in a tendency towards a reduction in V T /T i in comparison to placebo (P = 0.16). There was no diVerence in VO 2 , VCO 2 , T i , T e or RR between acetazolamide and sildenaWl (Table 1) . Acetazolamide increased V E , V T /T i , V E /VCO 2 and decreased P ET CO 2 compared to sildenaWl (Table 1; Fig. 2 ).
Hemodynamic responses at rest and during hypoxic exercise Exercising SaO 2 was improved with acetazolamide, but not with sildenaWl, compared to placebo (Table 2) . SildenaWl increased exercising heart rate compared to acetazolamide and placebo (Table 2) . SildenaWl reduced systolic blood pressure and mean arterial pressure when compared to placebo while there was no change in diastolic blood pressure during exercise between all conditions (Table 2 ). Right Fig. 1 Timeline of study. D drug intake, M meal intake ventricular systolic pressures measured before exercise tended to be reduced with sildenaWl when compared to placebo (PLA 18.2 § 2.1, SIL 14.0 § 1.2, ACZ 17.2 § 2.5 mmHg, P = 0.09). Right ventricular systolic pressures measured immediately after exercise were not signiWcantly diVerent between conditions (PLA 19.4 § 2.3, SIL 16.4 § 1.5, ACZ 16.5 § 1.7 mmHg) while right ventricular systolic pressures measured 10 min after exercise were reduced with sildenaWl (P = 0.04) and tended to be reduced with acetazolamide when compared to placebo (P = 0.07) (PLA 16.7 § 1.8, SIL 14.9 § 1.4, ACZ 14.9 § 1.6 mmHg).
Discussion
Acetazolamide increased V E and decreased breathing eYciency during hypoxic submaximal exercise. Although sildenaWl did not aVect breathing eYciency, there was a trend toward a blunted ventilatory response in comparison to placebo, possibly due to pulmonary vasodilation and/or a reduction in pulmonary arterial pressure and congestion.
It is generally reported that acetazolamide increases V E during hypoxic exercise (Garske et al. 2003; Jonk et al. 2007; McLellan et al. 1988; Schoene et al. 1983 ). In accordance with previous studies (Faoro et al. 2007a; Garske et al. 2003; Schoene et al. 1983) , we observed that chronic intake of acetazolamide attenuated the decline in SaO 2 during normobaric hypoxic exercise. Our observed acetazolamide-induced increase in V E was suYcient to reduce the fall in SaO 2 during hypoxic submaximal exercise, possibly due to increased alveolar and arterial oxygen tension. We also observed that the increase in V E was due to an increase in V T and a reduction in RR. Interestingly, there was an inverse correlation (r = ¡0.56, P = 0.02) between V E and SaO 2 during hypoxic exercise, indicating that individuals with greater SaO 2 were actually breathing less than individuals with low SaO 2 . This relationship was attenuated by acetazolamide (r = ¡0.40, P = 0.08). The increase in V E without changes in VCO 2 resulted in an increased V E /VCO 2 representing a reduced breathing eYciency, a Wnding previously observed during hypoxic exercise (Garske et al. 2003) . The observed decrease in RER with acetazolamide was also reported by others and was suggested to be caused by an altered CO 2 production kinetics (Faoro et al. 2007a; Schoene et al. 1983 ). Finally, acetazolamide had no eVect on right ventricular systolic pressure which is consistent with the results of Faoro et al. (2007a) who reported that acetazolamide does not aVect pulmonary hemodynamics.
Although there are some reports that sildenaWl does not aVect ventilation or breathing eYciency during normobaric or hypobaric hypoxic exercise in healthy individuals (Faoro et al. 2007b; Ricart et al. 2005) , sildenaWl has been observed to improve breathing eYciency during exercise in patients with heart failure (Bocchi et al. 2002; Guazzi et al. 2004; Lewis et al. 2007 ). This improvement in breathing eYciency in patients with heart failure was attributed to a decrease in central ventilatory drive and less likely due to an improved ventilation-perfusion matching (Lewis et al. 2007 ). In accordance with these results, we observed that sildenaWl induced a trend toward a blunted ventilatory response and reduced ventilatory drive to hypoxic submaximal exercise, which could be related to a reduction in pulmonary arterial pressures. This is supported by a near signiWcant inverse correlation between right ventricular systolic pressure and V E (r = ¡0.29, P = 0.07). Figure 3 shows the V E /VCO 2 and P ET CO 2 relationship in all participants for all conditions. The parabola curve Wtting the data was produced using the alveolar air equation as shown in Fig. 3 . Since these points all fall on the same curve across conditions, it suggests that there were no changes in the physiological dead space fraction of the breath (V D /V T ), which is consistent with minimal changes in breathing pattern and/or in ventilation-perfusion matching. We did observe a decrease in right ventricular systolic pressure measurements ranging from 11 to 23% with sildenaWl compared to placebo, which is consistent with previous observations that sildenaWl reduced pulmonary arterial pressure through inhibition of hypoxia-induced pulmonary vasoconstriction (Faoro et al. 2007b; Ghofrani et al. 2004; Reichenberger et al. 2007 ). Moreover, right ventricular systolic pressures were measured at rest and not during exercise, and it is therefore possible that the sildenaWl-induced reduction in pulmonary arterial pressures was greater during exercise. We also observed that acetazolamide tended to decrease right ventricular systolic pressure, possibly due to a reduced vasoconstriction from the elevated SaO 2 and PaO 2 . Studies examining the eVects of sildenaWl almost uniformly report an attenuated decline in SaO 2 during acute normobaric hypoxic exercise (Faoro et al. 2007b; Ghofrani et al. 2004; Hsu et al. 2006; Ricart et al. 2005; Snyder et al. 2008) . SildenaWl was reported to improve SaO 2 during acute normobaric hypoxic exercise at an ambient oxygen concentration of 10% (Faoro et al. 2007b; Ghofrani et al. 2004; Ricart et al. 2005 ) but did not change SaO 2 during acute normobaric hypoxic exercise in an altitude tent with an ambient oxygen concentration of 12.5% (Snyder et al. 2008) . Despite chronic intake of sildenaWl and the accompanying hemodynamic changes, we did not observe attenuation in the decline of SaO 2 during submaximal exercise following 18 h of hypoxic exposure. Failure to observe an improvement in SaO 2 with sildenaWl during hypoxic exercise may be explained by the combination of submaximal rather than maximal exercise intensity, less than 24 h of hypoxic exposure, as well as the milder hypoxia used in our protocol compared with studies that have either used an ambient oxygen concentration of 10% or an altitude above 5,000 m. Our intent was to examine the eVects of sildenaWl and acetazolamide that could apply to typical recreational or work-related hypoxic exposures of modest duration in non-acclimatized subjects such as search and rescue or skiing trips. We believe that the beneWts of sildenaWl are more likely to be seen during either: (1) several days of moderate hypoxic exposure, e.g. Richalet et al. (2005) , mediated by attenuation of pulmonary congestion, ventilation-perfusion mismatch and reduction in pulmonary arterial pressures; (2) Fig. 2 Ventilation (V E ), breathing eYciency (V E /VCO 2 ) and pressure of end-tidal CO 2 (P ET CO 2 ) during hypoxic submaximal exercise for placebo (white circles), sildenaWl (black squares) and acetazolamide (gray diamonds).
9 Placebo versus acetazolamide, ‡ sildenaWl versus acetazolamide (Faoro et al. 2007b; Ghofrani et al. 2004; Reichenberger et al. 2007) or (3) intense exercise in well-trained athletes under moderate or severe hypoxia where pulmonary vasodilating eVects of sildenaWl may be more relevant to exercise performance. This study was performed in an altitude tent (normobaric hypoxia) and therefore may not represent the true physiological response to high altitude (hypobaric hypoxia). In addition, small eVects of sildenaWl on exercise SaO 2 could have been missed due to limited power to detect small diVerences. Nonetheless it is evident that acetazolamide has greater eVects than sildenaWl on submaximal exercise SaO 2 following 18 h of moderate hypoxic exposure. It would be of interest to further compare the eVects of acetazolamide and sildenaWl on breathing eYciency and exercise performance at diVerent exercise intensities in a high altitude environment during several days of moderate or severe hypoxic exposure.
Conclusions
In conclusion, following 18 h of normobaric moderate hypoxic exposure, acetazolamide improved submaximal exercise SaO 2 while reducing breathing eYciency through an increase in ventilation. In contrast, sildenaWl did not signiWcantly improve exercise SaO 2 , but did not impair breathing eYciency and demonstrated a trend toward a blunted ventilatory response possibly due to a reduction in pulmonary arterial pressure and/or a reduction in ventilatory drive. 
